Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma



Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma

Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers report.

Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

31st March 2023

Form is (mal)function: Protein's shape lets bacteria disarm it

Read more
30th March 2023

Researchers discover a way to fight the aging process and cancer development

Read more
30th March 2023

Researchers identify cell type that could be key to preventing marrow transplant complication

Read more